Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma

Evaluation of response to treatment is a key aspect in cancer therapy. Response Evaluation Criteria in Solid Tumors (RECIST) are used in most oncology trials, but those criteria evaluate only unidimensional tumor measurements and disregard the extent of necrosis, which is the target of all effective locoregional therapies. Therefore, the European Association for the Study of the Liver (EASL) guidelines recommended that assessment of tumor response should incorporate the reduction in viable tumor burden. The current report provides an assessment of the agreement/concordance between both RECIST and the EASL guidelines for the evaluation of response to therapy.

[1]  Riccardo Lencioni,et al.  Design and endpoints of clinical trials in hepatocellular carcinoma. , 2008, Journal of the National Cancer Institute.

[2]  L Pagliaro,et al.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.

[3]  Carlo Bartolozzi,et al.  Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. , 2005, Radiology.

[4]  Eric P Tamm,et al.  CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. , 2004, AJR. American journal of roentgenology.

[5]  Yi-Cheng Chen,et al.  Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. , 2004, Gastroenterology.

[6]  B. Daniele,et al.  Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma , 2008 .

[7]  F. Miller,et al.  Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. , 2007, AJR. American journal of roentgenology.

[8]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[9]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[10]  J. Dickson,et al.  Prediction of clinical outcome in treated neuroendocrine tumours of carcinoid type using functional volumes on 111In-pentetreotide SPECT imaging , 2004, Nuclear medicine communications.

[11]  Haesun Choi.  Critical issues in response evaluation on computed tomography: Lessons from the gastrointestinal stromal tumor model , 2005, Current oncology reports.

[12]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[13]  Ramon Planas,et al.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial , 2002, The Lancet.

[14]  M. van Glabbeke,et al.  RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. , 2005, European journal of cancer.

[15]  J. Bruix,et al.  Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma , 2004, Hepatology.

[16]  Mark J. Ratain,et al.  Measuring response in a post-RECIST world: from black and white to shades of grey , 2006, Nature Reviews Cancer.

[17]  R. V. van Klaveren,et al.  Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. , 2004, Lung cancer.

[18]  T. Kawabe,et al.  A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. , 2005, Gastroenterology.

[19]  J. Bruix,et al.  Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival , 2003, Hepatology.

[20]  Carlo Bartolozzi,et al.  Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. , 2003, Radiology.

[21]  J. Doroshow,et al.  Drug development in oncology: classical cytotoxics and molecularly targeted agents. , 2006, British journal of clinical pharmacology.

[22]  J. Bruix,et al.  Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. , 2007, Journal of hepatology.

[23]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[24]  K. McHugh,et al.  Limitations with the response evaluation criteria in solid tumors (RECIST) guidance in disseminated pediatric malignancy , 2006, Pediatric Blood & Cancer.

[25]  M. Byrne,et al.  Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  M A Schneiderman,et al.  Historical and methodological developments in clinical trials at the National Cancer Institute. , 1990, Statistics in medicine.

[27]  L. Lasagna,et al.  Newer techniques and some problems in cooperative group studies. , 1960, National Cancer Institute monograph.

[28]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[29]  Robert J. Lewandowski,et al.  Treatment of Unresectable Primary and Metastatic Liver Cancer with Yttrium-90 Microspheres (TheraSphere®): Assessment of Hepatic Arterial Embolization , 2006, CardioVascular and Interventional Radiology.

[30]  L. Schwartz,et al.  Prostate Cancer Clinical Trial End Points: “RECIST”ing a Step Backwards , 2005, Clinical Cancer Research.

[31]  John Wong,et al.  Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma , 2002, Hepatology.

[32]  M. Buyse,et al.  Update in methodology and conduct of cancer clinical trials. , 2006, European journal of cancer.

[33]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[34]  E. Eisenhauer,et al.  RECIST revisited: a review of validation studies on tumour assessment. , 2006, European journal of cancer.

[35]  渡邉 裕一.  Tumor response to chemotherapy : The validity and reproducibility of RECIST guidelines in NSCLC patients , 2004 .

[36]  Effect of the introduction of minimum lesion size on interobserver reproducibility using RECIST guidelines in non‐small cell lung cancer patients , 2006, Cancer science.

[37]  J. Bruix,et al.  Is microbubble-enhanced ultrasonography sufficient for assessment of response to percutaneous treatment in patients with early hepatocellular carcinoma? , 2006, European Radiology.

[38]  A. Nowak.  CT, RECIST, and malignant pleural mesothelioma. , 2005, Lung cancer.

[39]  M. Latteri,et al.  Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. , 2005, Journal of hepatology.

[40]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .